[go: up one dir, main page]

WO2009009769A3 - Diagnosis of fetal abnormalities using nucleated red blood cells - Google Patents

Diagnosis of fetal abnormalities using nucleated red blood cells Download PDF

Info

Publication number
WO2009009769A3
WO2009009769A3 PCT/US2008/069879 US2008069879W WO2009009769A3 WO 2009009769 A3 WO2009009769 A3 WO 2009009769A3 US 2008069879 W US2008069879 W US 2008069879W WO 2009009769 A3 WO2009009769 A3 WO 2009009769A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood cells
red blood
diagnosis
nucleated red
fetal abnormalities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/069879
Other languages
French (fr)
Other versions
WO2009009769A2 (en
Inventor
Ravi Kapur
Diana Bianchi
Tom Barber
Mehmet Toner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Tufts Medical Center Inc
Artemis Health Inc
Curate Biosciences LLC
Original Assignee
General Hospital Corp
Tufts Medical Center Inc
GPB Scientific Inc
Artemis Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Tufts Medical Center Inc, GPB Scientific Inc, Artemis Health Inc filed Critical General Hospital Corp
Publication of WO2009009769A2 publication Critical patent/WO2009009769A2/en
Publication of WO2009009769A3 publication Critical patent/WO2009009769A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1029—Particle size
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for diagnosing a condition in a fetus by enriching and enumerating circulating red blood cells with the possible combination of results from maternal serum marker screens.
PCT/US2008/069879 2007-07-11 2008-07-11 Diagnosis of fetal abnormalities using nucleated red blood cells Ceased WO2009009769A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94922707P 2007-07-11 2007-07-11
US60/949,227 2007-07-11

Publications (2)

Publication Number Publication Date
WO2009009769A2 WO2009009769A2 (en) 2009-01-15
WO2009009769A3 true WO2009009769A3 (en) 2009-04-09

Family

ID=40229506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/069879 Ceased WO2009009769A2 (en) 2007-07-11 2008-07-11 Diagnosis of fetal abnormalities using nucleated red blood cells

Country Status (1)

Country Link
WO (1) WO2009009769A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163282B2 (en) 2010-05-18 2015-10-20 Natera, Inc. Methods for non-invasive prenatal ploidy calling

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003277153A1 (en) 2002-09-27 2004-04-19 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
AU2009279734A1 (en) 2008-08-04 2010-02-11 Natera, Inc. Methods for allele calling and ploidy calling
AU2010239131A1 (en) 2009-04-21 2011-11-17 Genetic Technologies Limited Methods for obtaining fetal genetic material
EP2473638B1 (en) 2009-09-30 2017-08-09 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
ES2770342T3 (en) 2010-12-22 2020-07-01 Natera Inc Noninvasive Prenatal Paternity Testing Procedures
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CN103235133B (en) * 2013-04-28 2014-11-19 成都中医药大学 Screening kit for abnormal diseases of chromosome 9 of fetus
CN103278633B (en) * 2013-04-28 2014-11-19 成都中医药大学 Kit for screening abortion history of pregnant woman
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
WO2015048535A1 (en) 2013-09-27 2015-04-02 Natera, Inc. Prenatal diagnostic resting standards
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US12492429B2 (en) 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20160130553A1 (en) 2014-05-15 2016-05-12 Kellbenx Incorporated PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US12202890B1 (en) 2014-11-07 2025-01-21 Kellbenx Incorporated Antibodies for detection and enrichment of fetal cells and their use
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
CN109477138A (en) 2016-04-15 2019-03-15 纳特拉公司 Lung cancer detection method
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US10894976B2 (en) 2017-02-21 2021-01-19 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
JP2021506342A (en) 2017-12-14 2021-02-22 ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． Evaluation of Graft Conformity for Transplantation
WO2019161244A1 (en) 2018-02-15 2019-08-22 Natera, Inc. Methods for isolating nucleic acids with size selection
EP3781714B1 (en) 2018-04-14 2026-01-07 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN110093247B (en) * 2019-05-07 2020-11-17 西安交通大学 Micro-fluidic chip for enriching and capturing target cells of different specifications and sizes
WO2020247263A1 (en) 2019-06-06 2020-12-10 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
CN110471426B (en) * 2019-09-02 2020-11-24 哈尔滨工程大学 Automatic collision avoidance method for unmanned intelligent vehicles based on quantum wolf pack algorithm

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059719A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Business methods for prenatal Diagnosis
US20070059716A1 (en) * 2005-09-15 2007-03-15 Ulysses Balis Methods for detecting fetal abnormality

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059719A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Business methods for prenatal Diagnosis
US20070059716A1 (en) * 2005-09-15 2007-03-15 Ulysses Balis Methods for detecting fetal abnormality

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRABCHI K. ET AL: "Quantification of all fetal nucleated cells in maternal blood in different cases of aneuploidies", CLINICAL GENETICS, vol. 69, 2006, pages 145 - 154 *
MAVROU A. ET AL: "Identification of nucleated red blood cells in maternal circulation: A second step in screening for fetal aneuploidies and pregnancy complications", PRENATAL DIAGNOSIS, vol. 27, 2007, pages 150 - 153 *
PERTL B. ET AL: "First trimester prenatal diagnosis: fetal cells in the maternal circulation", SEMINARS IN PERINATOLOGY, vol. 23, no. 5, October 1999 (1999-10-01), pages 393 - 402 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163282B2 (en) 2010-05-18 2015-10-20 Natera, Inc. Methods for non-invasive prenatal ploidy calling

Also Published As

Publication number Publication date
WO2009009769A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2009009769A3 (en) Diagnosis of fetal abnormalities using nucleated red blood cells
EA201290716A1 (en) METHODS AND COMPOSITIONS FOR NONINVASIVE PRENATAL DIAGNOSTICS OF FETUS ANEUPLOIDY
EP2161347A3 (en) Markers for prenatal diagnosis and monitoring
WO2005118852A3 (en) A marker for prenatal diagnosis and monitoring
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
EP2857527A3 (en) Enrichment and identification of fetal cells in maternal blood and ligands for such use
HK1206792A1 (en) Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
IN2012DN03139A (en)
WO2008014516A3 (en) Selection of cells using biomarkers
EP1689884A4 (en) METHODS OF PRENATAL DIAGNOSIS OF CHROMOSOMIC ANOMALIES
EP2657697A3 (en) Methods for determining the risk of chromosomal abnormality in a fetus
HK1208708A1 (en) Non-invasive method for detecting a fetal chromosomal aneuploidy
WO2007121276A3 (en) Enrichment of circulating fetal dna
WO2006034427A3 (en) Diagnosis of fetal aneuploidy
WO2007028155A3 (en) Fragment size distribution pattern of amniotic fluid cell-free fetal dna for prenatal diagnosis
WO2011143659A3 (en) Nucleic acid isolation methods
MXPA05010532A (en) Non-invasive prenatal genetic diagnosis using transcervical cells.
WO2007147074A3 (en) Use of highly parallel snp genotyping for fetal diagnosis
WO2012088456A3 (en) Methods for non-invasive prenatal paternity testing
WO2008132753A3 (en) Methods and kits for detecting fetal cells in the maternal blood
EP2863220A3 (en) Reducing/oxidizing activity of maternal urine as indicator of fetal gender related characteristics
WO2006024466A3 (en) Test device for the in vitro diagnosis of multi-analyte tests and the use thereof
WO2012027483A3 (en) Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood
Tan et al. Maternal hemoglobin level and red cell indices as predictors of gestational diabetes in a multi-ethnic Asian population
GB2427915B (en) Method of fetal cell enrichment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781738

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781738

Country of ref document: EP

Kind code of ref document: A2